Claims
- 1. A compound of formula I
- 2. A compound according to claim 1, wherein X is 1,4-phenylene, Y is —CH2—CH2—, R1 is phenyl monosubstituted in position para by a group R15 wherein R15 is straight chain C5-8alkyl; C2-8alkenyl; or straight chain or branched C1-8alkoxy optionally substituted by one C3-6cycloalkyl or by a phenyl group optionally substituted by up to three halogens; or R1 is para-monosubstituted phenyl substituted by a group of formula (a), (b) or (c), as defined in claim 1, R2 is C1-4alkyl optionally substituted on the terminal C atom by OH or a residue of formula (h) as defined above, R3 and R4 are hydrogen, and R5 is OH, or a salt thereof.
- 3. A compound according to claim 1 or 2, wherein R1 is phenyl monosubstituted in position para by a group of formula (a) as defined above, or a salt thereof.
- 4. A compound according to any one of claims 1 to 3, wherein Z is O, or a salt thereof.
- 5. A process for preparing a compound according to any one of claims 1 to 5 which process comprises removing the hydrolysable groups present in a compound of formula II
- 6. A compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.
- 7. A compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament.
- 8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier therefor.
- 9. A pharmaceutical combination comprising a) a first agent which is a compound according to any one of claims 1 to 4, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
- 10. A method for preventing or treating disorders or diseases mediated by lymphocytes, for preventing or treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases, for inhibiting or controlling deregulated angiogenesis, or for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject comprising administering to the subject in need thereof an effective amount of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
0212210.9 |
May 2002 |
GB |
|
0226624.5 |
Nov 2002 |
GB |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 60/432,704 (filed Dec. 10, 2002), U.K. patent application Number 0226624.5 (filed Nov. 14, 2002) and U.K. patent application Number 0212210.9 (filed May 27, 2002). The full disclosures of these applications are incorporated herein by reference in their entirety and for all purposes.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60432704 |
Dec 2002 |
US |